Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (4599)	10/20/2000 3:01:39 PM
From: Biomaven	Read Replies (1) of 10280

tommysdad, Great discussion. I hadn't thought of some of the possibilities you mentioned. A good example of how the simplistic view here isn't always right is the example of levalbuterol. The initial assumption was that the evil twin contributed to side effects, but not to efficacy, and was otherwise inert (or perhaps long-term deleterious). If this was the case, levalbuterol should be the equivalent of double the dose of albuterol, with side effects the same. (Or equivalently, half the side effects for an equally efficacious half-sized dose). However this is not how it worked in practice. Surprisingly 1/4 (instead of 1/2) the dose of Xopenex is equivalent to a full dose of albuterol, and the side effects were not cut in nearly the same 1:4 ratio. What this means is that the evil twin was an active player in the picture, somehow interfering with the absorption or activity of the good twin or otherwise counteracting its effect. (And further, the evil twin doesn't play that big a part in the short-term side effects). Moral: Everything is more complicated than it seems. <g> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next